Atlas Trials

Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

Clinical trial NCT06554613 · RECRUITING

Trial details

NCT number
NCT06554613
Sponsor
Second Affiliated Hospital of Nanchang University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer
Start date
2024-07-02
Primary completion
2026-12-01
Enrollment
156

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.